HIV medicine
Effectiveness and tolerability of dolutegravir/lamivudine in virologically suppressed people with HIV at 96 weeks in a multicentre cohort.
Inés Suárez-García, Belén Alejos, Cristina Moreno, Rosa de Miguel, Teresa Aldámiz-Echevarría, Lucio Jesús García-Fraile, María Tasias Pitarch, Desirée Pérez Martinez, Antonio Antela, Santiago Moreno, Inma Jarrín, CoRIS cohort
Published: 202510.1111/hiv.70183
Abstract
OBJECTIVE: To evaluate the effectiveness and tolerability of dolutegravir/lamivudine (DTG/3TC) at 96 weeks in virologically suppressed persons with HIV, both overall and across subgroups, within CoRIS, a large multicenter cohort in Spain, in 2018-202…
Preview only. Read the full abstract at the source